Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KERX
  • CUSIP: 49251510
Key Metrics:
  • Previous Close: $5.25
  • 50 Day Moving Average: $4.50
  • 200 Day Moving Average: $5.40
  • 52-Week Range: $2.80 - $7.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.55
  • P/E Growth: -0.04
  • Market Cap: $555.95M
  • Outstanding Shares: 105,895,000
  • Beta: 4.22
Profitability:
  • Net Margins: -590.50%
  • Return on Equity: -172.04%
  • Return on Assets: -63.87%
Debt:
  • Debt-to-Equity Ratio: 2.09%
  • Current Ratio: 8.66%
  • Quick Ratio: 6.97%
Additional Links:
Companies Related to Keryx Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.08)
Consensus Price Target: $8.21 (56.36% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2016JMP SecuritiesReiterated RatingOutperformView Rating Details
8/3/2016Cowen and CompanyReiterated RatingNeutralView Rating Details
8/2/2016Raymond James Financial Inc.Boost Price TargetOutperform$7.00 -> $10.00View Rating Details
8/2/2016Ladenburg ThalmannBoost Price TargetBuy$9.00 -> $10.00View Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/2/2016FBR & CoDowngradeOutperform -> Market Perform$16.00 -> $7.00View Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
8/1/2016Maxim GroupDowngradeBuy -> HoldView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50View Rating Details
2/26/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
2/19/2016Citigroup Inc.Lower Price Target$2.50 -> $1.80View Rating Details
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00View Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$25.00View Rating Details
5/6/2015MizuhoLower Price TargetBuy$25.00 -> $21.00View Rating Details
3/20/2015Oppenheimer Holdings Inc.Lower Price TargetOutperform$22.00 -> $18.00View Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.39 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.25)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.08)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-1.24 EPS
Next Year EPS Consensus Estimate: $-0.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.21)($0.21)($0.21)
Q3 20161($0.23)($0.23)($0.23)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Ownership Percentage: 3.08%
Institutional Ownership Percentage: 61.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline
globenewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class ... - GlobeNewswire (press release) (NASDAQ:KERX)
globenewswire.com - September 24 at 10:14 AM
News IconTime To Put On The Watch List? - Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Biogen Inc. (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:KERX)
voiceregistrar.com - September 24 at 10:14 AM
News IconSHAREHOLDER ALERT Levi Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class ... - EconoTimes (NASDAQ:KERX)
www.econotimes.com - September 23 at 5:27 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 23 at 5:27 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 – KERX (NASDAQ:KERX)
finance.yahoo.com - September 23 at 10:31 AM
News IconThe Statistics Don't Lie: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) Earnings Preview - The Voice Registrar (NASDAQ:KERX)
voiceregistrar.com - September 22 at 5:34 PM
finance.yahoo.com logoDeadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming October 3rd Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. (NASDAQ:KERX)
finance.yahoo.com - September 22 at 5:34 PM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 22 at 5:34 PM
News IconGrowth Analysis of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Newburgh Press (NASDAQ:KERX)
newburghpress.com - September 21 at 4:03 PM
News IconStock Tracker: Earnings & Estimates for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Frisco Fastball (NASDAQ:KERX)
friscofastball.com - September 21 at 4:03 PM
News IconActive biotech company shares in the news: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Halozyme Therapeutics ... - The Voice Registrar (NASDAQ:KERX)
voiceregistrar.com - September 21 at 4:03 PM
News IconBiotech Stocks Worth a Closer Look: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Nektar Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:KERX)
voiceregistrar.com - September 21 at 4:03 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - September 21 at 4:03 PM
finance.yahoo.com logoUPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 21 at 4:03 PM
finance.yahoo.com logoGPM Reminds Investors of the October 3rd Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 21 at 9:57 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 21 at 9:57 AM
finance.yahoo.com logoKeryx Biopharmaceuticals to Webcast its Presentation at Ladenburg Thalmann’s 2016 Healthcare Conference (NASDAQ:KERX)
finance.yahoo.com - September 21 at 9:57 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – KERX (NASDAQ:KERX)
finance.yahoo.com - September 19 at 5:48 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - September 19 at 5:48 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 19 at 5:48 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - September 19 at 10:21 AM
News IconEckrich, Operation Homefront and Jewel-Osco Partner to Honor Military Family (NASDAQ:KERX)
www.econotimes.com - September 18 at 5:32 PM
benzinga.com logoKERYX SHAREHOLDER ALERT BY FORMER LOUISIANA... (NASDAQ:KERX)
www.benzinga.com - September 17 at 5:30 PM
globenewswire.com logoKERYX ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in ... - GlobeNewswire (press release) (NASDAQ:KERX)
globenewswire.com - September 17 at 10:20 AM
businesswire.com logoDEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Upcoming ... - Business Wire (press release) (NASDAQ:KERX)
www.businesswire.com - September 17 at 10:20 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 17 at 10:20 AM
businesswire.com logoKERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff ... (NASDAQ:KERX)
www.businesswire.com - September 16 at 12:25 PM
finance.yahoo.com logoKERYX ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Action (NASDAQ:KERX)
finance.yahoo.com - September 16 at 12:25 PM
capitalcube.com logoETF’s with exposure to Keryx Biopharmaceuticals, Inc. : September 16, 2016 (NASDAQ:KERX)
www.capitalcube.com - September 16 at 12:25 PM
finance.yahoo.com logoDEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Upcoming Deadline (NASDAQ:KERX)
finance.yahoo.com - September 16 at 12:25 PM
businesswire.com logoRobbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Class ... - Business Wire (press release) (NASDAQ:KERX)
www.businesswire.com - September 15 at 3:41 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 15 at 9:00 AM
finance.yahoo.com logoRobbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:KERX)
finance.yahoo.com - September 14 at 5:53 PM
News IconWhat Do Analysts Think Of Keryx Biopharmaceuticals, Inc. (KERX)? - National Daily Press (NASDAQ:KERX)
www.nationaldailypress.com - September 14 at 10:01 AM
News IconINVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Actio... (NASDAQ:KERX)
ih.advfn.com - September 9 at 5:37 PM
finance.yahoo.com logoKERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx … (NASDAQ:KERX)
finance.yahoo.com - September 9 at 5:37 PM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 9 at 5:36 PM
News IconTop Biotechnology Stock Picking: Keryx Biopharmaceuticals Inc. (KERX), Vertex Pharmaceuticals Incorporated (VRTX) - National Daily Press (NASDAQ:KERX)
www.nationaldailypress.com - September 9 at 10:31 AM
benzinga.com logoJMP Reiterates Market Outperform Rating On Retrophin - Benzinga (NASDAQ:KERX)
www.benzinga.com - September 8 at 5:40 PM
prnewswire.com logoINVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline ... - PR Newswire (press release) (NASDAQ:KERX)
www.prnewswire.com - September 8 at 5:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - September 8 at 5:40 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 8 at 5:40 PM
finance.yahoo.com logoINVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Action - KERX (NASDAQ:KERX)
finance.yahoo.com - September 8 at 5:40 PM
4-traders.com logoGovernment of Canada : MP Cuzner to make a funding announcement (NASDAQ:KERX)
www.4-traders.com - September 8 at 9:43 AM
News IconRobbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, I... (NASDAQ:KERX)
ih.advfn.com - September 8 at 9:43 AM
finance.yahoo.com logoRobbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity (NASDAQ:KERX)
finance.yahoo.com - September 8 at 9:43 AM
finance.yahoo.com logoKERX DEADLINE: Hagens Berman Reminds Investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) of October 3, 2016 Lead Plaintiff Deadline and of Expanded Securities Case Class Period (NASDAQ:KERX)
finance.yahoo.com - September 8 at 9:43 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of ... - Yahoo Finance (NASDAQ:KERX)
finance.yahoo.com - September 7 at 9:16 AM
biz.yahoo.com logoKERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:KERX)
biz.yahoo.com - September 7 at 9:16 AM
finance.yahoo.com logoBrower Piven Alerts Shareholders of Upcoming Deadline in Class Action Lawsuit and Encourages Those with Losses from Investment in Keryx Pharmaceuticals, Inc. to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - September 6 at 5:48 PM

Social

Keryx Biopharmaceuticals (NASDAQ:KERX) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff